Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug971 | DFV890 Wiki | 0.58 |
drug2540 | Placebo for Camostat Mesilate Wiki | 0.58 |
drug686 | Camostat Mesilate Wiki | 0.18 |
Navigate: Correlations HPO
There are 3 clinical trials
The study will assess the efficacy and safety of DFV890 for the treatment of SARS-Cov-2 infected patients with COVID-19 pneumonia and impaired respiratory function.
Description: The APACHE II ("Acute Physiology And Chronic Health Evaluation II") is a severity-of-disease classification system. An integer score from 0 to 71 is computed based on several measurements; higher scores correspond to more severe disease and a higher risk of death. Worst case imputation for death will be applied.
Measure: APACHE II severity of disease score on Day 15 or on the day of discharge (whichever is earlier) Time: up to Day 15Description: C-reactive protein (CRP) is a blood test marker for inflammation in the body. For a standard CRP test, a normal reading is less than 10 milligram per liter (mg/L). It will be analyzed on a log-scale fitting a repeated measures mixed model including treatment group, study day, the three stratification factors and log transformed baseline CRP as a covariate.
Measure: Serum C-reactive protein (CRP) levels Time: up to Day 29Description: Clinical status is measured with the 9-point ordinal scale. The scoring is - Uninfected patients have a score 0 (no clinical or virological evidence of infection). - Ambulatory patients (not in hospital or in hospital and ready for discharge) can have a score 1 (no limitation of activities) or 2 (limitation of activities). - Hospitalized patients with mild disease can have score 3 (no oxygen therapy defined as SpO2 ≥ 94% on room air) or 4 (oxygen by mask or nasal prongs). - Hospitalized patients with severe disease can have score 5 (non-invasive ventilation or high-flow oxygen), 6 (intubation and mechanical ventilation) or 7 (ventilation + additional organ support - pressors, RRT (renal replacement therapy), ECMO (extracorporeal membrane oxygenation)). - Patients who die have a score 8.
Measure: Clinical status over time Time: up to Day 29Description: Proportion of participants not requiring mechanical ventilation for survival.
Measure: Proportion of participants not requiring mechanical ventilation for survival. Time: Day 15, Day 29Description: Clinical status is measured with the 9-point ordinal scale. The scoring is - Uninfected patients have a score 0 (no clinical or virological evidence of infection). - Ambulatory patients (not in hospital or in hospital and ready for discharge) can have a score 1 (no limitation of activities) or 2 (limitation of activities). - Hospitalized patients with mild disease can have score 3 (no oxygen therapy defined as SpO2 ≥ 94% on room air) or 4 (oxygen by mask or nasal prongs). - Hospitalized patients with severe disease can have score 5 (non-invasive ventilation or high-flow oxygen), 6 (intubation and mechanical ventilation) or 7 (ventilation + additional organ support - pressors, RRT (renal replacement therapy), ECMO (extracorporeal membrane oxygenation)). - Patients who die have a score 8.
Measure: Proportion of participants with at least one-point improvement from baseline in clinical status Time: Baseline, Day 15, Day 29This study is an adaptive, randomized, open-label, controlled clinical trial, performed worldwide in collaboration with WHO and INSERM.
Description: WHO 7-point ordinal scale: Not hospitalized, no limitations on activities; Not hospitalized, limitation on activities; Hospitalized, not requiring supplemental oxygen; Hospitalized, requiring supplemental oxygen; Hospitalized, on non-invasive ventilation or high flow oxygen devices; Hospitalized, on invasive mechanical ventilation or ECMO; Death
Measure: Improvement of clinical status on the ordinal 7-point severity-scale at day 15. Time: at day 15This study is a 4-arm, multicenter, randomized, partly double- blind, controlled trial to evaluate the safety and efficacy of convalescent serum (CP) or camostat mesylate with control or placebo in adult patients diagnosed with SARS-CoV-2 and high risk for moderate/severe COVID-19. The working hypothesis to be tested in the RES-Q-HR study is that the early use of convalescent plasma (CP) or camostat mesylate (Foipan®) reduces the likelihood of disease progression to modified WHO stages 4b-8 in SARS-CoV-2 positive adult patients at high risk of moderate or severe COVID-19 progression. The primary endpoint of the study is the cumulative number of individuals who progressed to or beyond category 4b on the modified WHO (World Health Organization) COVID-19 ordinal scale within 28 days after randomization.
Description: The primary endpoint of the study is the number of individuals whose clinical status is on the COVID-19 modified WHO ordinal scale ≥ 4b up to and including day 28
Measure: WHO ordinal Covid-19 scale up to day 28 Time: up to and including day 28Description: Cumulative number of persons in the respective treatment arms versus SoC/placebo in WHO categories 4b-8
Measure: Cumulative number WHO categories 4b-8 Time: day 8, day 14, day 56 and day 90Description: Cumulative number of persons in the respective treatment arms versus SoC/placebo in WHO categories 3-4a
Measure: Cumulative number WHO categories 3-4a Time: day 8, day 14, day 28, day 56 and day 90Description: Cumulative number of participants not hospitalized at day 90
Measure: Not hospitalized Time: at day 90Description: All-cause mortality at day 90
Measure: All-cause mortality Time: at day 90Description: Number of patient with SARS-CoV-2 reinfection up to day 90
Measure: Reinfection Time: up to day 90Description: Number of patient with secondary sclerosis cholangitis at day 90
Measure: Secondary sclerosing cholangitis (SSC) Time: at day 90Description: Number of patient with COVID-19 associated chronic pulmonary disease
Measure: chronic pulmonary disease as sequelae from COVID-19 Time: at day 90Description: The proportion of patients with remdesivir therapy
Measure: patients with remdesivir treatment Time: up to day 90Description: The clinical status on the WHO COVID-19 ordinal scale of at the start of remdesivir treatment WHO ordinal scale ranges from 0 to 8; whereas 0 = no COVID-19 infection and 8 = death
Measure: COVID-19 WHO status of patients at start of remdesivir treatment Time: up to day 90Description: The proportion of patients on dexamethasone therapy
Measure: patients with dexamethasone treatment Time: up to day 90Description: The clinical status on the WHO COVID-19 ordinal scale of at the start of dexamethasone treatment WHO ordinal scale ranges from 0 to 8; whereas 0 = no COVID-19 infection and 8 = death
Measure: COVID-19 WHO status of patients at start of dexamethasone treatment Time: up to day 90Description: Time to resolution of COVID-19 related symptoms (e.g. fever)
Measure: resolution of COVID-19 symptoms Time: until day of resolution up to day 90Description: Time to first negative SARS-CoV-2-PCR (polymerase chain reaction)
Measure: negative SARS-CoV-2-PCR test Time: until day of first negative test up to day 90Description: Duration of oxygen therapy (in days)
Measure: Oxygen therapy Time: number of days with oxygen therapy up to day 90Description: Frequency of occurrence of COVID-19 pneumonia
Measure: COVID-19 pneumonia Time: up to day 90Description: Percentage of participants in each group with need for mechanical ventilation
Measure: Percentage of participants requiring mechanical ventilation Time: up to day 90Description: Number of ventilation days per participant up to day 90
Measure: Number of ventilation days per participant up to day 90 Time: up to day 90Description: Duration of hospital stay (in days), duration in intensive care/intermediate care (IMC) (in days)
Measure: hospital stay and intensive care Time: up to day 90Description: All-cause mortality at day 28
Measure: Mortality Time: at day 28Description: Cumulative incidence of Serious Adverse Events (SAE) per group within 90 days follow up
Measure: SAEs Time: up to day 90Description: Cumulative incidence of grade 3/4 Adverse Events (AE) per group
Measure: Grade 3/4 AEs Time: up to day 90Description: SARS-CoV-2 antibody concentrations (IgA in g/l) in serum on day 8, day 14, day 90
Measure: SARS-CoV-2 antibody IgA concentrations Time: on day 8, day 14, day 90Description: SARS-CoV-2 antibody concentrations (IgG in g/l) in serum on day 8, day 14, day 90
Measure: SARS-CoV-2 antibody IgG concentrations Time: on day 8, day 14, day 90Description: SARS-CoV-2 neutralizing antibody titers in serum on day 8, day 14, day 90
Measure: SARS-CoV-2 neutralizing antibody titers Time: on day 8, day 14, day 90Description: Number of screening failures due to the lack of a suitable plasma preparation
Measure: Plasma treatment screening failures Time: up to day 8 (End of treatment)Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports